Paul Brunetta
Overview
Explore the profile of Paul Brunetta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
2518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou S, Brunetta P, Silvasstar J, Feldman G, Oromi N, Bull S
JMIR Mhealth Uhealth
. 2024 Oct;
12:e55239.
PMID: 39471372
Background: Despite the growing availability of smoking cessation apps, low engagement and cessation rates have remained a significant challenge. To address this issue, we used a user-centered design to iteratively...
2.
Berti A, Hillion S, Konig M, Casal Moura M, Hummel A, Carmona E, et al.
Arthritis Rheumatol
. 2022 Oct;
75(5):736-747.
PMID: 36281741
Objective: Autoreactive B cells are responsible for antineutrophil cytoplasmic antibody (ANCA) production in ANCA-associated vasculitis (AAV). Rituximab (RTX) depletes circulating B cells, including autoreactive B cells. We aimed to evaluate...
3.
Berti A, Hillion S, Hummel A, Son Y, Chriti N, Peikert T, et al.
JCI Insight
. 2021 Oct;
6(22).
PMID: 34618687
BACKGROUNDLittle is known about the autoreactive B cells in antineutrophil cytoplasmic antibody-associated (ANCA-associated) vasculitis (AAV). We aimed to investigate tolerance checkpoints of circulating antigen-specific proteinase 3-reactive (PR3+) B cells.METHODSMulticolor flow...
4.
Furie R, Aroca G, Cascino M, Garg J, Rovin B, Alvarez A, et al.
Ann Rheum Dis
. 2021 Oct;
81(1):100-107.
PMID: 34615636
Objective: Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody...
5.
Brogan P, Yeung R, Cleary G, Rangaraj S, Kasapcopur O, Hersh A, et al.
Arthritis Rheumatol
. 2021 Jun;
74(1):124-133.
PMID: 34164952
Objective: To assess the safety, tolerability, pharmacokinetics, and efficacy of rituximab (RTX) in pediatric patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Methods: The Pediatric Polyangiitis Rituximab Study...
6.
Owczarczyk K, Cascino M, Holweg C, Tew G, Ortmann W, Behrens T, et al.
JCI Insight
. 2020 Aug;
5(18).
PMID: 32841219
BACKGROUNDBaseline expression of FCRL5, a marker of naive and memory B cells, was shown to predict response to rituximab (RTX) in rheumatoid arthritis. This study investigated baseline expression of FCRL5...
7.
Redfield R, Jordan S, Busque S, Vincenti F, Woodle E, Desai N, et al.
Am J Transplant
. 2019 Jul;
19(11):3035-3045.
PMID: 31257724
The limited effectiveness of rituximab plus intravenous immunoglobulin (IVIG) in desensitization may be due to incomplete B cell depletion. Obinutuzumab is a type 2 anti-CD20 antibody that induces increased B...
8.
Kronbichler A, Leierer J, Shin J, Merkel P, Spiera R, Seo P, et al.
Arthritis Rheumatol
. 2019 Jun;
71(11):1888-1893.
PMID: 31216123
Objective: To assess the frequency of venous thromboembolism (VTE) events in the Rituximab in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (RAVE) trial and identify novel potential risk factors. Methods: VTE events...
9.
Gomez Mendez L, Cascino M, Katsumoto T, Brakeman P, Brunetta P, Jayne D, et al.
Lupus Sci Med
. 2019 May;
6(1):e000308.
PMID: 31080631
Objective: The outcome of participants with nephrotic syndrome in clinical trials of lupus nephritis has not been studied in detail. Methods: Collated data from two randomised controlled trials in lupus...
10.
Gomez Mendez L, Cascino M, Garg J, Katsumoto T, Brakeman P, DallEra M, et al.
Clin J Am Soc Nephrol
. 2018 Aug;
13(10):1502-1509.
PMID: 30089664
Background And Objectives: Incomplete peripheral blood B cell depletion after rituximab in lupus nephritis might correlate with inability to reduce tubulointerstitial lymphoid aggregates in the kidney, which together could be...